Auckland-based respiratory disease device and monitoring system maker Adherium has signed an agreement with the Medical Research Institute of New Zealand (MRINZ) for the supply of its Smartinhaler devices and software for an international clinical study.
The Smartinhaler platform will be used in a randomised control trial of the efficacy and safety of an ICS/LABA reliever therapy regimen in asthma. The study will take place in New Zealand, Australia, the UK and Italy.
